Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors.
Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors.
复制标题
KIT 和表皮生长因子受体在化疗难治性非精原细胞肿瘤中的表达。
DOI：
10.1093/annonc/mdg244
复制
发表时间：
2003
期刊：
影响因子：
--
通讯作者：
Einhorn,L
中科院分区：
文献类型：
--
作者：
Madani,A;Kemmer,K;Sweeney,C;Corless,C;Ulbright,T;Heinrich,M;Einhorn,L
背景大多数生殖细胞肿瘤（GCT）患者可以通过标准治疗治愈。可治愈和不可治愈的疾病之间的分子差异是未知的。我们研究了表达的KIT和表皮生长因子受体（EGFR），以确定其发病率在chemorefractory diseases.Patients和methodsWe回顾性分析了23例chemorefractory非恶性肿瘤GCT（15晚期复发和8转化畸胎瘤）。这23例患者均未通过初始化疗和/或手术治愈。对最近从转移部位获得的标本进行KIT和EGFR的免疫组织化学分析。PCR扩增物ofKIT外显子17的突变进行了筛选的变性高效液相色谱法和直接sequencing.ResultsKIT表达（≥10%的肿瘤显示膜或细胞质染色）在11 23 GCT患者[48%，95%置信区间（CI）26%至68%]的组合。在21例分析的患者中，在磷酸转移酶结构域（外显子17）中没有激活的KIT突变。EGFR表达（1+至3+）在15 23例GCT患者（65%; 95%CI 41%至82%hclussionsKIT和EGFR表达在一个显着比例难治性GCT。这些发现的意义将由正在进行的临床试验确定。
BackgroundThe majority of patients with germ-cell tumors (GCTs) are curable with standard therapy. The molecular differences between curable and incurable disease are unknown. We have studied the expression of KIT and the epidermal growth factor receptor (EGFR) to determine their incidence in chemorefractory disease.Patients and methodsWe retrospectively analyzed 23 patients with chemorefractory non-seminomatous GCTs (15 late relapse and eight transformed teratomas). None of these 23 patients were cured by their initial chemotherapy and/or surgery. Immunohistochemical analysis of KIT and EGFR was performed on the most recently available specimen from a metastatic site. PCR amplimers ofKITexon 17 were screened for mutations by a combination of denaturing high-performance liquid chromatography and direct sequencing.ResultsKIT was expressed (≥10% of the tumor displaying membranous or cytoplasmic staining) in 11 of 23 GCT patients [48%; 95% confidence interval (CI) 26% to 68%]. There were no activatingKITmutations in the phosphoryltransferase domain (exon 17) in 21 patients analyzed. EGFR was expressed (1+ to 3+) in 15 of 23 GCT patients (65%; 95% CI 41% to 82%).ConclusionsKIT and EGFR are expressed in a significant proportion of refractory GCTs. The significance of these findings will be determined by ongoing clinical trials.